Drevenhorn E, Hakansson A, Petersson K . A meta-analysis. ** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. If you are taking losartan you should avoid potassium-containing salt substitutes or... University of Cincinnati, Cincinnati, OH;3 University of Mississippi Medical Center, Jackson, MS;4 The binding of angiotensin II to an ATAlthough losartan and candesartan have, in several large randomized clinical trials, documented effect on CVD-risk reduction, no head-to-head comparison studies have been performed. , The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases, Candesartan: from left ventricular hypertrophy to heart failure, a global approach, A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension, Journal of the Renin-Angiotensin-Aldosterone System, Candesartan in the treatment of hypertension: what have we learnt in the last decade?, Comparative clinical‐ and cost‐effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta‐ and cost‐utility analysis, Cardiovascular Events in Subgroups of Patients During Primary Treatment of Hypertension With Candesartan or Losartan, In Vitro Antagonistic Properties of a New Angiotensin Type 1 Receptor Blocker, Azilsartan, in Receptor Binding and Function Studies, Journal of Pharmacology and Experimental Therapeutics, Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension, Combination Therapy with Candesartan Cilexetil 32 mg and Hydrochlorothiazide 25 mg Provides the Full Additive Antihypertensive Effect of the Components, Transport characteristics of candesartan in human intestinal Caco‐2 cell line, Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta‐analytical approach, Comparison of Angiotensin II Type 1 Receptor Antagonists in the Treatment of Essential Hypertension, Spotlight on the Pharmacoeconomics of Candesartan Cilexetil in Chronic Heart Failure and Hypertension1, Candesartan cilexetil – a review of effects on cardiovascular complications in hypertension and chronic heart failure, Scintillation Proximity Assay as a High-Throughput Method to Identify Slowly Dissociating Nonpeptide Ligand Binding to the GnRH Receptor, A Review of Olmesartan Medoxomil Monotherapy: Antihypertensive Efficacy Similar to That of Other Angiotensin II Receptor Blocker/Hydrochlorothiazide Combinations?, Kinetics of nonpeptide antagonist binding to the human gonadotropin-releasing hormone receptor: Implications for structure–activity relationships and insurmountable antagonism, A placebo‐controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36‐h ambulatory blood pressure monitoring, Clinical update: The role of angiotensin II receptor blockers in patients with left ventricular dysfunction (Part II of II), Preserving cardiac function in the hypertensive patient: why renal parameters hold the key, Angiotensin II Receptor Antagonists Alone and Combined with Hydrochlorothiazide, A Meta-Analytical Approach to the Efficacy of Antihypertensive Drugs in Reducing Blood Pressure, Angiotensin II receptor antagonists: Role in hypertension, cardiovascular disease, and renoprotection, Angiotensin Receptor Blockers and Target-Organ Protection Beyond Blood Pressure Control, Clinical Pharmacology of Angiotensin II Receptor Antagonists, Antagonistas de los receptores de la angiotensina II.
University of Pittsburgh School of Medicine, Pittsburgh, PA;2 There is no difference in their safety/tolerability profile.
However, in our study the frequency of laboratory data did not differ markedly between the two groups, suggesting similar need of medical attention at baseline.We have adjusted for differences in observed CVD risk between the two groups at inclusion. Los, losartan; Can, candesartan.Chronic ischemic heart disease, myocardial infarction, and stroke showed similar cumulative incidence in both groups (Changes of losartan and candesartan doses during follow-up. After 5 min rest in either the supine or sitting position an appropriate sized cuff is placed on the over arm.
and you may need to create a new Wiley Online Library account.Enter your email address below and we will send you your usernameIf the address matches an existing account you will receive an email with instructions to retrieve your username However, the large number of patients may compensate for this weakness.When including patients over a longer time span, the possibility of variations in the patient handling may be a confounder.
University of Mississippi Medical Center, Jackson, MS;4
Department of Pharmacy, University of Utah, Salt Lake City, UT;5 and AstraZeneca LP, Chesterbrook, PA6From the Departments of Preventive Medicine and Internal Medicine, Rush Presbyterian St. Luke's Medical Center, Chicago, IL;1 There were no deaths during this trial. Atacand (candesartan) is a good blood pressure-lowering medicine that protects your kidneys and has few side effects. When several readings are performed, the calculated mean is recorded. The fact that CC consistently lowered trough, peak, and 48 hours post‐dose BP compared to losartan indicated true differences between the two drugs. Should beta blockers remain first choice in the treatment of primary hypertension? Both losartan and candesartan have beneficial remodelling effects on hypertrophic myocardium.Furthermore, candesartan has reported positive effects on risk markers such as high oxidative stress and increased coagulability compared to losartan, which may explain the lower risk for CVD complications.There was no difference between the two treatment groups in blood pressure throughout the study, with an average blood pressure of approximately 145/85 mm Hg in both groups. Department of Pharmacy, University of Utah, Salt Lake City, UT;5 and AstraZeneca LP, Chesterbrook, PA6From the Departments of Preventive Medicine and Internal Medicine, Rush Presbyterian St. Luke's Medical Center, Chicago, IL;1 University of Cincinnati, Cincinnati, OH;3 Lacourciere Y, Asmar R . All 72 primary care centres prescribed both losartan and candesartan, although in various ratios. The annual frequency of inclusion to the losartan or candesartan group from 1999 to 2007 was, however, similar. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).